Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ionis Pharmaceuticals Inc. Common Stock vs Invesco Ltd. — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $43.32 (market cap $7.10B), while Invesco Ltd. trades at $27.87 (market cap $12.33B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 3.08% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and Invesco Ltd. for 77 Days on average.
| IONS | IVZ | |
|---|---|---|
Market Cap | $7.10B | $12.33B |
Volume | 2,027,457 | 4,127,288 |
Sector | Health | Financials |
52-Week High | $86.50 | $33.31 |
52-Week Low | $42.38 | $22.44 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $6.66B | $22.50B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Invesco (IVZ) trades at $28.92, down 1.16% with bearish technical signals despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $6.38B in 2025 but negative net margins of -0.93%. Analyst consensus remains cautiously optimistic with a $33.17 price target and no sell ratings, while technical indicators suggest near-term pressure with support at $28.
Investment outlook balances strong asset growth momentum (AUM up 4.7% to $2.56T in August 2026) against profitability challenges. Key opportunities include dividend yield and ETF expansion, while risks center on margin pressure and market volatility. The stock presents value potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
